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Background: Cell-transplantation therapies have attracted attention as treatments for skeletal-muscle disorders;
however, such research has been severely limited by poor cell survival. Tissue engineering offers a potential
solution to this problem by providing biomaterial adjuvants that improve survival and engraftment of donor cells.
Methods: In this study, we investigated the use of intra-muscular transplantation of mesoangioblasts
(vessel-associated progenitor cells), delivered with an injectable hydrogel biomaterial directly into the tibialis
anterior (TA) muscle of acutely injured or dystrophic mice. The hydrogel cell carrier, made from a polyethylene
glycol-fibrinogen (PF) matrix, is polymerized in situ together with mesoangioblasts to form a resorbable
cellularized implant.
Results: Mice treated with PF and mesoangioblasts showed enhanced cell engraftment as a result of increased
survival and differentiation compared with the same cell population injected in aqueous saline solution.
Conclusion: Both PF and mesoangioblasts are currently undergoing separate clinical trials: their combined use may
increase chances of efficacy for localized disorders of skeletal muscle.
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Tissue engineeringBackground
Skeletal muscles are primarily responsible for controlling
voluntary movement and posture. They can self-repair
in response to moderate injuries, but are not able to re-
generate when significant loss of tissue occurs in exten-
sive trauma or surgery. Similarly, they cannot sustain
repeated cycles of degeneration/regeneration, such as
occurs in severe forms of muscular dystrophy [1], which
are difficult diseases to treat. Such conditions affect the* Correspondence: cannata@uniroma2.it; g.cossu@ucl.ac.uk; cesare.gargioli@
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reproduction in any medium, provided the orlarge majority of skeletal muscles, which are composed
of large multinucleated post-mitotic fibers surrounded
by a thick basal lamina. Delivery of cells or vectors into
these muscles still represents a significant challenge [1].
Reconstructive strategies, such as autologous muscle
transplantation and intra-muscular injection of progeni-
tor cells yield only modest therapeutic outcomes, mainly
because the tissue often presents an inflamed or sclerotic
environment that results in poor survival and only mod-
est integration of engrafted cells, and the cells are also
targets of an immune reaction [2-5]. Moreover, the
in vitro cultivation history of the grafted cells can also
negatively affect the efficacy of myoblast transplantation,
although this may be prevented by culturing cells on soft
hydrogels [6]. Among the new therapeutic strategies forLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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is becoming a promising clinical option [7]. Systemic
injections of vessel-associated progenitor cells called
mesoangioblasts, which overcome some of the problems
associated with myoblast intra-muscular injections, has
been shown to result in better long-term survival of
donor cells, and in partial restoration of muscle struc-
ture and function in dystrophic mice [8,9] and dogs [10].
The efficacy of mesoangioblasts is mainly due to their
ability to cross the endothelium and to migrate exten-
sively in the interstitial space, where they are recruited
by regenerating muscle to reconstitute new functional
myofibers. Consequently, a phase I/II clinical trial based
on intra-arterial delivery of donor-derived mesoan-
gioblasts is currently ongoing in children affected by
Duchene Muscular Dystrophy at the San Raffaele Hos-
pital in Milan (EudraCT no. 2011-000176-33).
A completely different approach using cell transplant-
ation (that is, tissue engineering), may be useful for
whole-muscle reconstruction after severe damage caused
by traumatic injury or surgical ablation [11,12]. Tissue
engineering uses two main components: the cells them-
selves, and biomaterials in which the cells are embedded
[11]. To support optimal in vivo muscle differentiation,
the biomaterials should possess characteristics such as
bioactivity, cell-mediated biodegradability, minimal cyto-
toxicity, and controllable properties including stiffness
[13]. With these issues in mind, natural components of
the extracellular matrix (ECM) have been reconstituted
as biomaterials that mimic the microenvironment of
skeletal muscle and thus support better regeneration.
Many different polymers, of both natural and synthetic
origins, have previously been used as scaffolds for the re-
generation of skeletal and cardiac muscle. In cardiac repair,
for example, many scaffolds have been tested in animal
trials with rats and dogs, but very few are being tested in
human clinical trials [14,15]. Nevertheless, compared with
direct myocardial injection of cells alone, it is strikingly
clear that tissue-engineering strategies offer better pre-
clinical results, including augmenting the engrafted cardio-
myocyte population and improving the contractile function
of the ischemic heart [16]. Likewise, in the field of skeletal-
muscle regeneration, Rossi and colleagues reported simi-
larly good results with biomaterials and tissue engineering.
These authors used freshly isolated myoblasts and hyalur-
onic acid ester-based hydrogels, polymerized in situ, to
promote improved reconstruction of a partially ablated
skeletal-muscle injury [17].
In the current investigation, we evaluated an approach
based upon local delivery of mesoangioblasts that was
facilitated by a semi-synthetic hydrogel made from poly-
ethylene glycol (PEG) and fibrinogen. This PEG-
fibrinogen (PF) hydrogel has a proven track record in
three-dimensional cell culture, in cardiac cell therapy andtissue engineering [18]. One advantage of the PF hydrogel
is its ability to undergo controlled and localized liquid-to-
solid transition (gelation) in the presence of a cell suspen-
sion inside a muscle injury. Another very important fea-
ture of the PF hydrogel is its chemical composition; the
PEG enables control over the material properties and the
fibrinogen provides inherent bioactivity, including cell-
adhesion motifs and protease-degradation sites [19]. We
tested different PF formulations, embedding mesoangio-
blasts within them and injecting the grafts into acutely
injured muscle and also into dystrophic muscle at an
advanced stage of the disease, in order to evaluate the abil-




Ethics approval for the animal experiments was obtained
from the Italian Ministry of Health (protocol #163/2011-B;
released on 16 September 2011) and all experiments were
conducted in accordance with the rules of good animal
experimentation (IACUC, number 432, dated 12 March
2006).
Preparation of mesoangioblasts and culture conditions
Mesoangioblasts were cultured at 37°C (5% CO2) in
petri dishes with DMEM (Dulbecco’s modified Eagle’s
medium with GlutaMAX; Gibco-BRL,Gaithersburg, MD,
USA), supplemented with heat-inactivated 10% FCS
(EuroClone), 100 IU/ml penicillin and 100 mg/ml
streptomycin [20]. Mesoangioblasts were transduced
with third-generation lentiviral vectors encoding the nu-
clear β-Galactosidase. and mesoangioblasts expressing
nuclear lacZ (nlacZ-mesoangioblasts) were cultured and
used for in vitro differentiation or intra-muscular injec-
tion [8].
Polyethylene glycol-fibrinogen
PEG-fibrinogen was produced and polymerized as
described previously [19]. Briefly, PEG-fibrinogen was pre-
pared at a desired concentration and diluted with sterile
PBS as required. A photoinitiator (Igracure™ 2959; Ciba
Specialty Chemicals, USA) was added to the PEG-
fibrinogen mixture at a final concentration of 0.1% w/v.
Cells were added at the desired concentration and the so-
lution was immediately exposed to UV light (365 nm,
4–5 mW/cm2) for 5 minutes for the in vitro experiments.
In vivo experiments were exposed to UV light (365 nm,
200 mW/cm2) using a hand-held light gun (LED-200;
Electro-lite Corp., Bethel, CT USA) for 1 minute.
Animals and treatments
Rag2 γ-chain null mice (4 months old) and α-sarcogly-
can knockout/severe combined immunodeficiency beige
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for intra-muscular injection. Briefly, mice were anesthe-
tized with an intra-muscular injection of physiologic sa-
line 10 ml/kg containing ketamine 5 mg/ml and xylazine
1 mg/ml. For the liquid nitrogen (N2) muscle-crush in-
jury, a small skin incision was made over the tibialis
anterior (TA) muscle of anesthetized mice. A liquid-
nitrogen-cooled needle (0.20 mm diameter) was inserted
along the craniocaudal axis of the TA twice, 30 seconds
for each insertion. For intra-muscular cell delivery, ap-
proximately 3 × 105 nlacZ-mesoangioblasts were injected
into the TA via a 0.20 mm diameter needle inserted along
the craniocaudal axis of the muscle. For PF-embedded
nlacZ-mesoangioblast injections, a limited incision was
made on the medial side of the leg to separate the TA
from the skin and to allow in vivo PF photopolymeriza-
tion. A subgroup of animals was injected intraperitone-
ally with 5-bromo-2-deoxyuridine (BrdU) 100 mg/kg
(RPN 20; GE Healthcare, Princeton, NJ, USA) to label
proliferating cells 2 hours after mesoangioblast trans-
plantation. The BrdU-labeled mice were killed 48 hours
after cell injection.
Cell apoptosis
The presence of apoptotic cells was examined using ter-
minal deoxynucleotidyl transferase dUTP nick-end la-
beling (TUNEL) staining (Roche Diagnostics, Basel,
Switzerland) in 10 μm cryosections. Positive control sec-
tions were treated with DNaseI (Roche Diagnostics,
Basel, Switzerland) for 20 minutes at 37°C. Sections
were incubated with the TUNEL reagent at 37°C
for 30 minutes before being counterstained with 4,6-
diamidino-2-phenylindole (DAPI).
Immunohistochemistry
The tissue samples were fixed in 4% paraformaldehyde
for 30 minutes at 4°C and washed in PBS, embedded in
optimal cutting temperature compound, and flash-
frozen in liquid-nitrogen-cooled isopentane. Sections
were cut at a thickness of 8 μm on a cryostat (Leica,
Heerbrugg, Switzerland) and washed with buffer (PBS
containing 0.2% Triton X-100). The sections were then
incubated with primary antibody (rabbit anti-laminin;
Sigma-Aldrich, St Louis, MO, USA) diluted to a final
concentration of 1:100 with blocking buffer (PBS con-
taining 0.2% Triton X-100 and 20% heat-inactivated goat
serum) for 20 minutes at room temperature. Sections
were washed with washing solution (PBS containing
0.2% Triton X-100 and 1% BSA), and then incubated
with the secondary antibody (horseradish peroxidase-
conjugated goat anti-rabbit; Chemicon International
Inc., Temecula, CA, USA), diluted 1:500 in 20% goat
serum. The immune reaction was developed using 3-
amino-9 ethylcarbazole substrate (AEC; Sigma-Aldrich).Afterwards, the sections were stained with X-Gal to
reveal β-galactosidase-positive cells as described previ-
ously [22]. Briefly, the sections were washed twice with
PBS for 5 minutes each and incubated for 24 hours at
37°C with an X-Gal working solution. This solution is
composed of the X-Gal stock solution (X-Gal 40 mg/ml
in N,N-dimethyl formamide, which was stored at −20°C
and protected from light) diluted 1 in 40 in X-Gal dilu-
tion buffer (crystalline potassium ferricyanide 5 mmol/l,
potassium ferricyanide trihydrate 5 mmol/l, and magne-
sium chloride 2 mmol/l in PBS, which was protected
from light, and stored at 4°C). Sections were washed
twice with PBS for 5–10 minutes each, and then covered
directly with aqueous mounting medium (Aqua Poly/
Mount; Polysciences Inc., Warrington, PA, USA) The
lacZ-positive nuclei were counted in five randomly
selected fields of three different non-adjacent transverse
sections from the largest TA portion taken from three
mice per experimental group.Immunofluorescence experiments
Immunofluorescence procedures were performed essen-
tially as described previously [22]. Briefly, the specimens
were prepared as described above, and then incubated
with primary antibodies diluted with blocking buffer for
20 minutes at room temperature. The primary anti-
bodies used were: mouse anti-α-SG (Ad1/20A6; Vector
Laboratories Inc., Burlingame, CA, USA) 1:100 dilution,
rabbit anti-laminin (#9393; Sigma-Aldrich) at 1:500,
rabbit anti-lacZ (Cappel Laboratories, Durham, NC,
USA) 1:100, mouse anti-Pax7 and anti-Myosin Heavy
Chain (MF20) (Developmental Studies Hybridoma Bank,
Iowa City, IA, USA) 1:100. After several washes with
buffer, sections were incubated with secondary anti-
bodies diluted with blocking buffer for 1 hour at room
temperature. The secondary antibodies (all used at
1:500) were anti-mouse FITC (Chemicon International
Inc.), anti-rabbit Alexa488, and anti-rat Alexa488 (both
Molecular Probes, Eugene, OR, USA). Sections were
counterstained with DAPI to detect nuclei, washed
several times with wash buffer, and mounted (Vector-
shield; Vector Laboratories Inc.). To visualize BrdU,
a commercial kit was used, and sections were treated
with nuclease/anti-BrdU solution provided in the kit
(RPN20, GE Healthcare, Princeton, NJ, USA) for 1 hour
at room temperature in accordance with the manufac-
turer’s instructions. Sections were washed three times in
PBS, and incubated for 30 minutes at room temperature
with Alexa Fluor 488 secondary antibody against mouse
(Molecular Probes). Sections were counterstained with
40,6-diamidino-2-phenylindole (DAPI), washed in PBS,
and mounted as described above.
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Tissue samples (n = 3 for each time point per group)
of TA treated with PF-embedded mesoangioblasts from
α-SG null mice were homogenized in liquid nitrogen,
mixed with lysis buffer (50 mmol/l Tris/HCl, pH 7.4,
1 mmol/l EDTA, 1 mmol/l EGTA, 1% Triton X-100,
1 mmol/l), and protease inhibitor cocktail (Sigma-
Aldrich), and separated by centrifugation at 12,000 g for
10 minutes at 4°C to remove the nuclei and cellular
debris. Protein concentrations were determined by
bicinchoninic acid (BCA) protein assay (Pierce Biotech-
nology Inc., Rockford, IL, USA) using BSA as a standard.
Total homogenates were separated by SDS-PAGE. For
western blotting analysis, proteins were transferred to
membranes (Immobilon; Amersham Biosciences Inc.,
Piscataway, NJ, USA), saturated with blocking solution
(1% BSA and 0.1% Tween-20 (Sigma-Aldrich) in PBS)
and hybridized with cleaved caspase-3 rabbit monoclonal
antibody (#9669; Cell Signaling Technology, Danvers,
MA, USA), α-SG mouse monoclonal antibody (Ad1/
20A6; Vector Laboratories) or lacZ polyclonal antibody
(#55976; Cappel Laboratories) at 1:1,000 dilution, or
with GAPDH monoclonal antibody (GAPDH-71.1;
Sigma-Aldrich) at 1:10,000 dilution for 1 hour at
room temperature. The blots were washed three timesFigure 1 Mesoangioblasts cultured in polyethylene glycol-fibrinogen
8 mg/ml PF hydrogel, giving rise to a robust three-dimensional myofiber n
fibers; staining is with an antibody against myosin heavy chain (MyHC; red)
(DAPI; blue). (D) Scanning electron microscopy image revealing the presen
hydrogel. Scale bar: (A) 200 μm, (B) 50 μm and (C) 10 μm.(15 minutes each at room temperature) with blocking
solution, and then reacted with anti-mouse or anti-
rabbit secondary antibody conjugated with HRP (Bio-
Rad Laboratories, Inc., Hercules, CA, USA) at 1:3,000
dilution for 1 hour at room temperature. The blots were
then washed three times, and finally visualized with an
enhanced chemiluminescent immunoblotting detection
system (Pierce Biotechnology Inc).
Statistical analysis
Statistical significance of the differences between means
was assessed by one-way analysis of variance (ANOVA)
followed by the Student-Newman-Keuls test to deter-
mine which groups were significantly different from the
others. When only two groups had to be compared, the
unpaired Student’s t-test was used. P<0.05 was consid-
ered significant. Values are expressed as means ± stand-
ard deviation (SD).
Results
Polyethylene glycol-fibrinogen ameliorates in vitro muscle
differentiation of mesoangioblasts
Initially different hydrogels [23-25] and different myo-
genic cells were tested to assess different combinations
of scaffold and cell that would promote muscle(PF) hydrogels. (A,B) Phase-contrast images of mesoangioblasts in
etwork. (C) Immunofluorescence showing multinucleated muscle
and nuclei counterstaining with 4,6-diamidino-2-phenylindole
ce of differentiating skeletal-muscle fibers (red arrows) within the PF
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ited good differentiation capabilities when cultured in
PF hydrogel [19] compared with other biomaterials
such as fibrin or TG-PEG (see Additional file 1: Figure
S1). For the present work, we choose mesoangioblasts
(vessel-associated mesoderm progenitors that are distinct
from satellite cells, but are still able to undergo robust myo-
genesis in vivo and in vitro, and that are currently in phase
I/II clinical trials [22,26,27]), as our myogenic stem/pro-
genitor cell. We used these to evaluate the influence of PF
on skeletal muscle cell differentiation, and to evaluate the
possibility of using mesoangioblasts plus PF as a com-
bination approach for translational clinical applications.
Mesoangioblasts, together with a PF formulation that
results in a matrix with a stiffness that has been optimized
for muscle differentiation [28], were tested prior to our
in vivo experiments, using different concentrations of the
PF precursor ranging from 4 to 12 mg/ml; the optimal
composition in terms of cell attachment and myogenic dif-
ferentiation was found to be 8 mg/ml (see Additional file 1:
Figure S2). As part of our in vitro testing, the mesoangio-
blasts were transduced with a lentiviral vector expressing
nuclear β-galactosidase (nlacZ-mesoangioblasts) for easierFigure 2 Long-term engraftment of mesoangioblasts in PBS and of p
injected intramuscularly into injured tibialis anterior (TA) muscle. Sec
respectively of treatment with nuclear (n)lacZ mesoangioblasts in PBS (A-C
analyses revealed a higher number of lacZ-positive cells in TA treated with
mesoangioblasts. (H) High-magnification views of X-Gal and laminin stainin
the host’s mature regenerating muscle fibers (arrow) in TA injected with PF
presented lac-Z positive cells mainly located in the extracellular matrix (arro
nlacZ-positive nuclei detected in five randomly selected fields of different,
TA. (I,J) Mean ± SD of nlacZ-positive nuclei (I) in the whole TA (cell engraft
Black bars indicate mesoangioblasts injected in PBS, and white bars indicat
treatment. Differences were significant (P<0.05) by ANOVA. Scale bar: (A–C,tracking. The nlacZ-mesoangioblasts (3 × 105) were sus-
pended in PF precursor solution (8 mg/ml) and cast in
silicone moulds by photopolymerization. Three days
after gelation in regular culture, the PF constructs
exhibited a homogeneous distribution of differentiated
mesoangioblast-derived myofibers forming a robust
three-dimensional network (Figure 1A,B). The PF
hydrogels supported mesoangioblast adhesion and dif-
ferentiation, as shown by immunofluorescence analyses for
myosin heavy chain in spontaneously contracting myofi-
bers (Figure 1C; Additional file 2: movie 1). Under the
scanning electron microscope, the differentiated mesoan-
gioblasts were seen to be organized into mature muscle
fibers embedded within the PF hydrogels (Figure 1D).
Polyethylene glycol-fibrinogen scaffold enhances
mesoangioblast-mediated regeneration after freeze injury
PF hydrogels (8 mg/ml) were used as an in vivo carrier
for transplantation of nlacZ-mesoangioblasts (3 × 105)
(PF-embedded mesoangioblasts) by intra-muscular injec-
tion after liquid nitrogen-induced injury to the TA
of immunodeficient Rag2 γ-chain null mice [29] (these
mice were used to prevent an immune response toolyethylene glycol-fibrinogen (PF)-embedded mesoangioblasts
tions of injured TA from Rag2 γ-chain null mice after 1, 3, and 5 weeks,
) or in PF (E-G) stained with X-Gal (blue) and laminin (red). Histological
the PF mesoangioblasts, compared with TA treated with the PBS
g showing the localization of lacZ-positive nuclei at the periphery of
mesoangioblasts. (D) The muscle treated with PBS mesoangioblast
w) of the TA muscle fibers. The histograms show the number of
non-adjacent sections (n = 3 mice per group) of X-Gal/laminin-stained
ment evaluation) and (J) inside myofibers (cell integration evaluation).
e mesoangioblasts injected in PF, analyzed at 1, 3, and 5 weeks after
E–G) 500 μm, (D,H) 20 μm.
Figure 3 (See legend on next page.)
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Figure 3 Survival and proliferation of implanted mesoangioblasts in injured tibialis anterior (TA) muscle of Rag2 γ-chain null mice.
Shown are representative sections 48 hours after intra-muscular injection with nuclear (n)lacZ- mesoangioblasts in (A-F) PBS or (G-L) polyethylene
glycol-fibrinogen (PF). Graft survival is documented by X-Gal (blue) and laminin (red) staining. The results show higher lacZ-positive cell
engraftment in TA treated with the PF mesoangioblasts (G,J) than with the PBS mesoangioblasts (A,D). The high-magnification regions (black
squares) reveal the localization of lacZ-positive nuclei; these are at the centre of the host’s regenerating muscle fibers (black arrowheads) in the
TA muscle treated with the PF mesoangioblasts (J), whereas they are mainly located in the extracellular matrix in the TA muscle treated with PBS
mesoangioblasts (D). Proliferation and apoptosis was assessed by staining with 5-bromo-2-deoxyuridine (BrdU;green) (B,H) and terminal dUTP
nick-end labeling (TUNEL; red) (C,I); both sets include a nuclear counterstain with 4,6-diamidino-2-phenylindole (DAPI). The decrease in apoptosis
in TA sections treated with PF mesoangioblasts (I) is striking compared with sections treated with PBS mesoangioblasts (C). High-magnification
regions (white arrows) of the BrdU- and TUNEL-labelld sections imaged by fluorescence under phase-contrast microscopy show proliferating and
apoptotic mesoangioblasts in PBS (E,F) and PF (K,L), juxtaposed with the regenerating host muscle fibers. Scale bar: (A,B,C,G,H,I) 500 μm, (D,E,F,J,K,
L) 40 μm, (insets) 50 μm.
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after injection of mesoangioblasts in PF or in PBS, in
order to evaluate time-dependent regeneration of the
TA muscle. Engraftment of mesoangioblasts in the re-
generating muscle was analyzed in TA sections by stain-
ing with X-Gal and anti-laminin antibodies that
recognize the basal lamina surrounding muscle fibers.
Histological analysis showed that the number of lacZ-
positive cells was higher in animals treated with PF-
embedded mesoangioblasts (Figure 2E-G) compared
with controls treated with mesoangioblasts in PBS
(Figure 2A-C). At higher magnifications, the mesoan-
gioblasts appeared mainly localized in the ECM of the
muscle treated with PBS mesoangioblasts, whereas the
PF mesoangioblasts had mainly fused with regenerating
fibers. After 3 and 5 weeks after PF mesoangioblasts
treatment, most of the lacZ-positive nuclei were cen-
trally located within the fibers, and some of the trans-
planted cells already occupied a sub-sarcolemmal
position in the regenerated fibers (Figure 2H, arrow).
By contrast, the injuries treated with PBS mesoangio-
blasts exhibited significantly fewer nuclei inside newly
formed muscle fibers (Figure 2D, arrow); at 5 weeks
after injection 110 ± 19 nuclei were scored inside the
TA fibers injected with PF mesoangioblasts, compared
with 33 ± 6 nuclei in those treated with PBS mesoan-
gioblasts (P<0.01) (Figure 2J). Quantitative analysis of
nlacZ-positive nuclei per tissue cross-section confirmed
the effect of PF in promoting cell engraftment and fu-
sion of mesoangioblasts into the regenerating muscle
fibers: at 5 weeks, there were 160 ± 11 nuclei in the
PF mesoangioblasts versus 90 ± 8 nuclei in the PBS
mesoangioblasts, with the difference being significant
(P<0.05) by ANOVA (Figure 2I,J). Moreover, we could
detect nlacZ-positive cells adjacent to muscle fibers
and expressing Pax7 (muscle satellite cell specific mar-
ker), indicating that they were replenishing the satellite-
cell pool (see Additional file 3: Figure S3). The number
of nlacZ+/Pax7+ cells was also higher in TA muscles
injected with the PF mesoangioblasts compared with the
PBS mesoangioblasts.Polyethylene glycol-fibrinogen enhances survival of
mesoangioblasts in freeze injury
The improved mesoangioblast engraftment (Figure 2)
associated with the PF hydrogel carrier could be due to
reduced cell death and/or enhanced proliferation. To
differentiate between these two possibilities, nlacZ-
mesoangioblasts (3 × 105) were injected intramuscularly
into the injured TA of Rag2 γ-chain null mice that
were also treated with the thymidine analog BrdU. The
BrdU was incorporated in actively proliferating cells
(Figure 3B,E,H,K), which were also assayed by TUNEL
nuclear staining that reveals cell death by apoptosis
(Figure 3C,F,I,L). Mesoangioblasts delivered using PF
hydrogels exhibited a much lower number (7 ± l/section)
of apoptotic nlacZ-positive cells (P<0.01 by ANOVA
(Figure 3I,J), compared with PBS mesoangioblasts (45 ±
4/section) (Figure 3C,F). The mesoangioblast prolifera-
tion, as indicated by BrdU incorporation, did not seem
to be affected by the PF hydrogel carrier, indicating that
protection from apoptosis rather than increased prolif-
eration was the cause of the enhanced engraftment
(Figure 4A). To further confirm the anti-apoptotic effect
of PF, expression of caspase-3 protein was evaluated.
Caspase-3 is a member of the cysteine–aspartic acid prote-
ase family that plays a central role in the execution-phase
of cell apoptosis. Mice that were killed 48 hours after intra-
muscular injection of mesoangioblasts in PBS exhibited
much higher levels of activated caspase-3 expression com-
pared with the group injected with PF mesoangioblasts or
the untreated sham group (Figure 4B,C).
Polyethylene glycol-fibrinogen hydrogel improves
efficacy of mesoangioblasts in muscular dystrophy
The combination of PF hydrogels and mesoangioblasts
was also tested as a locally administered cell therapy for
repair of dystrophic muscle at an advanced stage of the
disease. Although systemic intra-arterial distribution
remains the obvious way to target many muscles in dif-
fuse forms of muscular dystrophy, local administration
may be a simpler and more efficacious option for loca-
lized forms affecting only a few muscles, such as
Figure 4 Quantitative analysis of cell proliferation and
apoptosis for mesoangioblasts in PBS and embedded into
polyethylene glycol-fibrinogen (PF) injected into injured tibialis
anterior (TA) muscle. (A) Number of cells positive for lacZ, bromo-2-
deoxyuridine (BrdU) and terminal dUTP nick-end labeling (TUNEL) in five
randomly selected, non-adjacent sections of the injured TA from Rag2
γ-chain null mice, 48 hours after injection of nuclear (n)lacZ
mesoangioblasts in PBS (black bars) or in PF (white bars). The histogram
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this is already being tested in patients. Accordingly, we
administered mesoangioblasts intramuscularly with or
without PF in 12-month-old dystrophic mice. These
relatively old α-SGKO/SCIDbg mice were chosen be-
cause they develop a progressive and more severe mus-
cular dystrophy compared with younger mice or withreveals that the total number of lacZ+ and BrdU+ cells was not
significantly different but the number of apoptotic (TUNEL+) cells was
reduced by several fold when cells were injected in PF hydrogel
(*P<0.01 by ANOVA). (B) Western blotting (n = 3, one representative
shown in the figure) of cleaved caspase-3 on total protein extracts from
the different treatments of injured TA muscle samples from three
different Rag2 γ-chain null mice. The data reveal a robust increase in
expression of caspase-3 in the TA treated with PBS mesoangioblasts
compared with the TA treated with PF mesoangioblasts or sham
controls. (C) The caspase-3/glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) ratio band densitometry data from five different western blots
revealed 10-fold higher caspase-3 protein expression level in TA samples
injected with PBS mesoangioblasts (white bar) compared with TA
samples treated with PF mesoangioblasts (chequered bar). (*P<0.01)
between the assessed samples (ANOVA).other strains such as the mdx mouse [21]. Moreover, the
sclerosis and reduced microvessel network in these ani-
mals impair the efficacy of several alternative treatments
[22]. The nlacZ-mesoangioblast grafts (3 × 105 cells)
were injected directly into chronically inflamed and
sclerotic TA regions typical of the advanced stages of the
disease; this represents a more hostile environment for
donor cells and, unfortunately, is a common finding in
patients with the most severe forms of muscular dys-
trophy. Immunohistochemistry for lacZ and laminin
showed increased engraftment and survival of nlacZ-
positive mesoangioblasts when injected with PF
(Figure 5E-G) compared with those injected in PBS
(Figure 5A-C). Histological analyses of dystrophic
muscle 5 weeks after the treatment showed enhanced
mesoangioblast integration into regenerating muscle
fibers when the PF hydrogel carrier was used
(Figure 5H), compared with the PBS carrier (Figure 5D).
Laminin staining highlighted that there was better
organization of regenerated muscle fibers in the TA trea-
ted with the PF mesoangioblasts, with an increased
number of nlacZ-positive nucleated fibers, whereas the
animals treated with PBS mesoangioblasts exhibited
many nlacZ-positive cells still present in the extracellular
compartment surrounding the fibers. Quantitative ana-
lysis showed a consistent increase in the number of inte-
grated mesoangioblasts inside the regenerated host
muscle fibers when they were injected with PF: 27 ± 7
PBS mesoangioblasts per section versus 88 ± 8 PF
mesoangioblasts per section (P<0.01) (Figure 5J) and
an higher overall number of mesoangioblasts with PF
(118 ± 9 PF mesoangioblasts and 51 ± 6 PBS mesoangio-
blasts) (P<0,05) (Figure 5I), which was also confirmed by
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(Figure 5K,L).
Polyethylene glycol-fibrinogen ameliorates
mesoangioblast-derived α-SG expression in muscular
dystrophy
Sections of TA from dystrophic αSGKO/SCIDbg mice
(12 months old) were examined for α-SG expression
after treatment with mesoangioblasts (with or withoutFigure 5 (See legend on next page.)PF carrier). Immunofluorescence at 5 weeks after
mesoangioblast injection showed partial recovery of
α-SG expression (sarcolemma-associated protein sur-
rounding the myofibers) in dystrophic TA muscles
(Figure 6). The expression of α-SG protein was more
abundant in sections of TA treated with the PF
mesoangioblasts (Figure 6B,D) than with the PBS
mesoangioblasts group (Figure 6A,C). Although the
α-SG in muscles of αSGKO mice treated with PF
(See figure on previous page.)
Figure 5 Survival and engraftment of mesoangioblasts in a dystrophic mouse model. Shown are different time-point samples (1, 3, and 5
weeks, respectively) of the dystrophic tibialis anterior (TA) muscles from 12-month-old α-sarcoglycan null mice treated (n = 18 per group) with
intra-muscular injections of nuclear (n)lacZ mesoangioblasts in PBS (A-C) or polyethylene glycol-fibrinogen (PF) (E-G). X-Gal staining is shown in
blue and laminin immunostaining in red. Histological analysis showed a higher number of lacZ+ cells in the TA muscle treated with the PF
mesoangioblasts (E-G) compared with the PBS mesoangioblasts (A-C). High magnification of X-Gal and laminin staining reveals an amelioration
of the muscle morphology, showing the localization of lacZ-positive nuclei at the periphery of the host’s regenerating muscle fibers (arrow) for
the TA injected with the PF mesoangioblasts (H), whereas donor nuclei are mainly located in the extracellular matrix (arrow) in the TA treated
with PBS mesoangioblasts (D). Quantitative analysis of the total number of nlacZ+ nuclei on X-Gal/laminin-stained TA sections reveals higher
mesoangioblast engraftment at each time point in the TA muscles treated with PF mesoangioblasts, (I) and ameliorated integration of PF
mesoangioblasts into host regenerated myofibers (J). The number of mesoangioblasts in PBS-injected TA (black bars) and PF-injected TA (white
bars) was documented at 1, 3, and 5 weeks after treatment (*P<0.05 by ANOVA test). Counting analysis was performed by scoring lacZ-positive
labeled cells under a phase-contrast microscope (× 40) in five randomly selected fields of different non-adjacent sections for three mice per
group. (K) The representative western blots for lacZ in total protein extracts from three different treated dystrophic TA muscles (n = 5, one
representative shown in the figure) show the progressive increase of lacZ expression in the TA muscle treated with PF mesoangioblasts
compared with the samples treated with PBS mesoangioblasts. (L) Densitometric analysis of the lacZ/GAPDH ratio from five different western
blots confirms the histological data analysis, and documents a steady increase in lacZ protein as a function of engraftment time; the influence of
the PF carrier on survival and integration of nlacZ-mesoangioblasts is also evident (*P<0.05 by ANOVA test). Scale bar: (A, B, C, E, F, G) 500 μm,
(D, H) 20 μm.
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level of protein expression approached those found in
the sham controls (wild-type mice treated with PBS
injection) (Figure 6E). Quantitative analyses using
western blotting densitometry confirmed significantly
(P<0.05 by ANOVA test) increased expression of α-SG
in dystrophic mice treated with PF mesoangioblasts
(over 50%) compared with the PBS mesoangioblasts
group (12.5%) (Figure 6F).
Discussion
Various pathological conditions, such as primary or
acquired myopathies, can lead to considerable degener-
ation in and/or loss of skeletal-muscle tissue. Because of
its limited capacity for self-repair, reconstruction or re-
generation of skeletal muscle often requires exogenous
treatments [1]. In particular, skeletal muscle in the
advanced stages of muscular diseases cannot regenerate,
and the accumulation of fat and connective tissue that
replaces the muscle tissue hinders the efficacy of novel
treatments such as cell or gene therapy and even drug
delivery. Recently, the implantation of an engineered
skeletal muscle has been proposed as an alternative
strategy for treating advanced-stage muscle pathologies.
Engineered-muscle explants offer the possibility of im-
mediate structural repair, prolonged implant survival,
and accelerated functional recovery [12].
In this study, we investigated a tissue-engineering ap-
proach that is capable of producing enriched donor cell en-
graftment into skeletal muscle, either after an acute injury
or in the more difficult case of advanced-stage muscular
dystrophy. We combined a photopolymerizable PF hydro-
gel carrier with mesoangioblast cells to provide an inject-
able tissue-engineering treatment option. The PF matrix
was tested in vitro along with a number of other suitable
injectable hydrogel biomaterials and cell types. Ultimately,it was the combination of myogenic cells and PF hydrogels
that produced the most promising in vitro results, with a
thick tri-dimensional network of differentiated myofibers.
The human mesoangioblasts embedded into PF showed
good myogenic differentiation. Based on our in vitro data,
the combination of mesoangioblasts and PF was tested in
an acute injury model and in a chronic dystrophic mouse
model. Although mesoangioblasts show good engraftment
in damaged and dystrophic muscle because of their ability
to fuse with regenerating myofibers, the injectable PF
carrier significantly enhanced this engraftment, and fur-
thermore the PF-embedded mesoangioblasts were able to
partly replenish the muscle satellite-cell niche. This effect
was due mainly to the encapsulating and protective envir-
onment provided by the PF surrounding the embedded
mesoangioblasts. This dense resorbable hydrogel milieu
provided immediate and timely protection from host in-
flammation, preventing apoptosis of the cells, without
interfering with cell proliferation or impeding long-term
graft survival, both in acutely damaged muscle, and in dys-
trophic muscle at an advanced stage of the disease. Rossi
and colleagues recently reported the effect of a photo-
crosslinked hyaluronic acid-based hydrogel (hyaluronic
acid-photoinitiator; HA-PI). This biomaterial improved the
ability of myogenic precursor cells to restore muscle tissue
after ablation, leading to functional recovery of injected
cell-derived myofibers and to the repopulation of the
satellite-cell niche [17]. Moreover, despite using different
hydrogels (HA-PI and PF), the range of elasticity to mimic
the skeletal-muscle tissue environment (in our condition
8 mg/ml) for both biomaterials is similar, ranging between
150 and 200 Pa. Therefore, even following different routes
in terms of the types of cells transplanted and the hydrogel
used as scaffold, the results obtained strongly support the
evidence that the skeletal muscle tissue-engineering
approach could have important clinical applications in
Figure 6 Expression analysis of α-sarcoglycan (α-SG) on dystrophic tibialis anterior (TA) muscle sections from α-SG null mice. α-SG
immunostaining on TA sections from α-SG null mice 5 weeks after treatment with mesoangioblasts in PBS (A,C) or with mesoangioblasts in polyethylene
glycol-fibrinogen (PF) carrier (B, D); immunofluorescence of the α-SG is red and that of lacZ is green, with the 4,6-diamidino-2-phenylindole (DAPI) nuclear
counterstain being blue (C,D). The number of α-SG positive fibers was increased with the PF mesoangioblaststreatment and localized in proximity to lacZ-
positive engrafted myofibers. (E) Western blotting analysis for α-SG in total protein extracts from three different treated dystrophic TA muscles (n = 5, one
representative shown in the figure), revealed that the α-SG expression in the dystrophic TA muscle treated with PF mesoangioblasts was higher than that
in TA muscle treated with PBS mesoangioblasts, and was closer to the level seen in wild-type controls (Cont). (F) The α-SG/glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) ratio densitometry analysis from five different western blots revealed higher α-SG protein expression level in the dystrophic TA
samples treated with PF mesoangioblasts, reaching a level slightly above 50% of the level seen in wild-type mice (*P<0.05 by ANOVA test of the
considered samples). Scale bar: (A-D) 50 μm.
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muscles.
Conclusion
The data described in this work provide demonstration of
the improved efficacy of mesoangioblast-mediated cell
therapy when cells are injected in a resorbable biomaterial
such as PF. This material protects injected cells from the
apoptosis they would normally undergo in the inflamed or
sclerotic muscle environment that is encountered in acute
or chronic pathologies of such tissue. Thus, exploiting the
features of PF to promote better mesoangioblast engraft-
ment and muscle regeneration may result in a significant
benefit for patients with localized forms of muscular dys-
trophy or those with acquired disorders that lead to severedamage of skeletal muscles, including hernia, sphincter
disorders, and surgical small-muscle ablations.Additional files
Additional file 1: Figure S1. Comparison between different material
and myogenic cells, indicating PF as the best supporting three-
dimensional (3D) environment for myogenic precursors muscle
differentiation. Fibrin, TG-polyethelene glycol (PEG) and PEG-fibrinogen
(PF) hydrogels were also analyzed (at 5 days culture) with different
myogenic cells: C2C12 (A,D,G), muscle satellite cells (B,E,H) and
mesoangioblasts (C,F,I). (A-F) Within fibrin and TG-PEG hydrogels,
numerous undifferentiated cells (arrowheads) or undifferentiated
aggregates (asterisks) and some formed myotubes (arrows) were
observed for all cell type tested, while PF (G-I) seemed to be a suitable
3D environment, promoting muscle differentiation, as revealed by a
complete 3D network of tick-differentiated myofibers with few
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http://www.skeletalmusclejournal.com/content/2/1/24undifferentiated cells. Insets show enlarged view of undifferentiated
(arrowhead) and differentiated (arrows) cells Scale bar: (A-I) 200 μm,
(insets) 50 μm. Figure S2 Myogenic differentiation in 3D PF
environment (8 mg/ml) between mouse and human
mesoangioblasts, revealed by myosin heavy chain (MyHC)
immunofluorescence. (A) PF-embedded mouse mesoangioblasts (after
5 days of culture) showed a thick three-dimensional network of MyHC
positive (red) fibers composed of large mesoangioblast nuclei (arrows).
(B) Similar differentiation ability was observed in human mesoangioblasts
(at 5 days of culture) embedded in PF (8mg/ml). Nuclei are labeled in
blue by 4,6-diamidino-2-phenylindole (DAPI) nuclear counterstaining. (A,
B)Scale bar: 20 μm. Figure S3 PF enhances mesoangiobasts derived
satellite cell poll replenishment. Double immunofluorescence for lacZ
(green) and Pax7 (red) on section of αsarcoglycan (αS-G) null mice
transplanted TA, 5 weeks after injection. PBS injected mesoangioblasts
(A) and PF-embedded mesoangioblasts (B) are identified as satellite cells
by co-expression of Pax7 and nuclear (n)lacZ, and appear orange in the
merged image (arrows) while endogenous satellite cells appear red
(arrowhead). (C)The histogram quantifies lacZ+/Pax7+ cells as a
percentage of total Pax7-positive cells in five randomly selected fields of
different non-adjacent sections for three mice per group (*P<0.05 by
ANOVA test). (A,B) Scale bar 50μm [23,25,30].
Additional file 2: Movie 1. Contracting myotube in 8 mg/ml
polyethelene glycol-fibrinogen (PF). Movie showing a mesoangioblasts
derived contracting myotube embedded into PF hydrogel.
Additional file 3: Movie 2. Differentiated muscle fibers in 8 mg/ml
polyethelene glycol-fibrinogen (PF). Movie revealing different focal
plan demonstrating three-dimensional myofiber network produced by
PF-embedded mesoangioblasts.
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